drugset

drugset / Trial / NCT05057897

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

NCT05057897 ↗

Phase 4 Terminated 34 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.

Timeline

Start: 2022-01-31
Primary completion: 2023-04-19
Completion: 2023-04-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1222	Vaccine	—	Intramuscular

Indications